Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou's president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST.
加利福尼亚州伯克利，2025年1月7日（环球新闻）-- Caribou Biosciences, Inc.（纳斯达克：CRBU），一家领先的临床阶段CRISPR基因组编辑生物制药公司，今天宣布，Caribou的总裁兼首席执行官Rachel Haurwitz博士，计划在2025年1月16日（星期四）上午10:30（太平洋标准时间）在第43届摩根大通医疗会议上进行企业更新报告。
For more information and a link to the live webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the event.
有关更多信息和直播网络研讨会的链接，请访问Caribou官网的活动页面。事件结束后，网络研讨会将在Caribou官网上保留30天。
About Caribou's novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
关于Caribou的新一代CRISPR平台
CRISPR基因编辑利用易于设计的模块化生物工具对活细胞中的DNA进行修改。2类CRISPR系统有两个基本元件：切割DNA的核酸酶蛋白和引导核酸酶生成特定部位双链断裂的RNA分子，这导致在目标基因组位点进行编辑。CRISPR系统能够编辑意外的基因组位点，称为脱靶编辑，这可能对细胞功能和表现型产生有害影响。对此挑战，Caribou开发了CRISPR杂化RNA-DNA引导（chRDNAs；发音为“chardonnays”），与全 RNA 引导相比，这些引导实现了更精确的基因组编辑。Caribou正在利用其chRDNA技术的力量进行高效的多重编辑，以开发CRISPR编辑的疗法。
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit .
关于Caribou Biosciences, Inc.
Caribou生物科学是一家临床阶段的CRISPR基因编辑生物制药公司，致力于为患有严重疾病的患者开发变革性疗法。该公司的基因编辑平台，包括其Cas12a chRDNA技术，使得能够以更高的精确度开发保护性细胞疗法，以可能提高对抗疾病的活性。Caribou正在推进其CAR-t平台中的现成细胞疗法管线，作为可供患有血液恶性肿瘤和自身免疫疾病患者使用的治疗方案。关注我们 @CaribouBio 并访问。
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Caribou生物科学公司，联系方式：
投资者：
艾米·菲古罗亚，CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
媒体：
佩吉·沃瓦尔德，博士
media@cariboubio.com
